Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants

NCT02824315 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: AL-335
DRUG: Odalasvir (ODV)
DRUG: Simeprevir (SMV)

Sponsor

Janssen Research & Development, LLC